
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc has demonstrated significant growth potential, highlighted by a 41% quarter-over-quarter increase in volumes for its NeXT Personal Dx in Q4'25, surpassing expectations and indicating strong demand for its genomic sequencing services. The company's recent acquisition of Medicare coverage for its proprietary NeXT Personal MRD test, particularly for breast cancer, further solidifies its market position and is expected to enhance volume growth as marketing efforts are ramped up in collaboration with its partner, Tempus. Additionally, the demonstrated efficacy of NeXT Personal in detecting minimal residual disease with a notable performance in early cancer recurrence detection adds to the fundamental strength behind Personalis's growth trajectory.
Bears say
Personalis Inc. faces a negative outlook primarily due to a downward revision of its revenue guidance for 2025, with expected revenue now ranging from $68 million to $73 million, reflecting a year-on-year decline of 12% to 5%. The company has encountered significant challenges, including a slowdown in the biopharma sector and logistical issues with global sample handling, which have negatively impacted its operational performance. Moreover, ongoing substantial losses and existing debt on its balance sheet raise concerns about Personalis's ability to generate sufficient revenue for profitability in the foreseeable future.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares